Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver
disease with many metabolic comorbidities, such as obesity, diabetes, and cardiovascular …

Non-alcoholic fatty liver disease (NAFLD) and its progressive inflammatory form non-
alcoholic steatohepatitis (NASH) are major health challenges due to a significant increase in …

Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease throughout the
world [1]. It is currently considered as the hepatic manifestation of metabolic syndrome and …

Inflammation and metabolic dysfunction are hallmarks of the progression of non-alcoholic
fatty liver disease (NAFLD), which is the fastest-growing liver disease worldwide. Emerging …

The pathogenesis of NAFLD is complex and diverse, involving multiple signaling pathways
and cytokines from various organs. Hepatokines, stellakines, adipokines, and myokines …

Abstract Non-alcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver
disease (NAFLD), is characterised by chronic liver inflammation, which can further progress …

Nonalcoholic steatohepatitis (NASH) is an advanced stage of fatty liver disease
characterized by liver damage, inflammation, and fibrosis. Although neutrophil infiltration is …

Growing research evidence suggests that elevated TLR2 is closely related to the occurrence
and development of nonalcoholic steatohepatitis (NASH). However, a little is known about …

Nonalcoholic fatty liver disease (NAFLD), a leading chronic disease worldwide, affects
approximately a quarter of the global population. Nonalcoholic steatohepatitis (NASH) is an …

Objective Low-grade chronic inflammation emerges as a potent driver of insulin resistance
and glucose dysregulation in obesity and associated non-alcoholic fatty liver disease …